ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting

    Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry

    Abdullah Faiq1, Payam Noroozi Farhadi1, Jesse Wilkerson2, Nastaran Bayat1, Anna Jansen3, Kathryn Rose4, Lukasz Itert5, Anne Johnson6, Christine Parks7, Edward H. Giannini8, Hermine I. Brunner9, Bob Goldberg10, Richard Morris4, Frederick W. Miller1 and Lisa G. Rider1, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2Social and Scientific Systems, Inc., Research Triangle Park, NC, 3Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, 4Social and Scientific Systems, Inc., Durham, NC, 5Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9PRCSG, Cincinnati, OH, 10The Myositis Association, Alexandria, VA

    Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
  • Abstract Number: 2227 • 2014 ACR/ARHP Annual Meeting

    Physical Impairment in Patients with Idiopathic Inflammatory Myopathies Is Predicted By the American College of Rheumatology Functional Status Measure

    Laura Cleary1, Leslie J. Crofford2, Archana Srinivas1, Heather Bush1, Catherine Starnes1, Qian Fan1, Jidan Duan1, Kirk Jenkins1, Natasha Fraser1, Matthew Rutledge1 and Beatriz Hanaoka3, 1University of Kentucky, Lexington, KY, 2Div of Rheumatology & Immunology, Vanderbilt University, Nashville, TN, 3Rheumatology, University of Kentucky, Lexington, KY

    Background/Purpose  The American College of Rheumatology classification criteria of functional status (ACR-FS) in Rheumatoid Arthritis is used as a measure of the consequences of impairment…
  • Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting

    The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement

    I.M. Markusse1, J. Meijs2, B. de Boer2, A. a. Schouffoer1, N. Ajmone Marsan3, L. J. M. Kroft4, M. K. Ninaber5, T. W. J. Huizinga2 and J.K. de Vries-Bouwstra6, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Cardiology, Leiden University Medical Center, Leiden, Netherlands, 4Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, 5Pulmonology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…
  • Abstract Number: 1327 • 2014 ACR/ARHP Annual Meeting

    Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis

    Melissa R. Bussey1, Gabrielle A. Morgan2, Maria C. Amoruso2, Bahram Rahmani3 and Lauren M. Pachman4, 1Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, 2Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, 3Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose:  Orbital myositis (OM), an inflammatory disease affecting the extra-ocular muscles, typically presents in the third decade.  It more commonly affects females and is extremely…
  • Abstract Number: 1263 • 2014 ACR/ARHP Annual Meeting

    Evidence for the Involvement of NK Cells in Antisynthetase Syndrome

    Baptiste Hervier1, Yves Allenbach2, Mikael Perez3, Hervé Devilliers4, Fleur Cohen-Aubart5, Zahir Amoura6, Werner Stenzel7, Isabelle Cremer8, Olivier Benveniste2 and Vincent Vieillard1, 1INSERM UMR-S 1135, UPMC, Paris, France, 2UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 3UMR-S 1138, INSERM & UPMC, Paris, France, 4CHU de Dijon, Dijon, France, 5Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, 6Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 7Department of Neuropathology, Charite Hospital, Berlin, Germany, 8INSERM UMR-S 1138, INSERM & UPMC, Paris, France

    Background/Purpose Antisynthetase syndrome (aSS) is characterized by the association of interstitial lung disease and myositis with anti-tRNA-synthetase autoantibodies. Its pathogenesis remains unknown, especially regarding the…
  • Abstract Number: 1262 • 2014 ACR/ARHP Annual Meeting

    Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto-Antibodies

    Yves Allenbach1,2,3, Aude Rigolet3, Bruno Eymard4, Tanya Stojkovic4, Anthony. Behin4, Pascal Laforet4, Peter Hufnagl5, Norman Zerbe6, Thierry Maisonobe7, Kuberaka Mariampillai8, Serge Herson8, Olivier Benveniste2,3 and Werner Stenzel9, 1Neuropathology, Charite Hospital, Berlin, Germany, 2UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, 3Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 4Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 5Pathology departmen, Charite Hospital, Berlin, Germany, 6Department of Pathology, Charite Hospital, Berlin, Germany, 7Neuropathology, Pitie-Salpetriere Hospital, Paris, France, 8Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, 9Department of Neuropathology, Charite Hospital, Berlin, Germany

    Background/Purpose: Necrotizing auto-immune myopathies (NAM) are a group of acquired idiopathic inflammatory myopathies characterized by severe muscle weakness and no or mild extra-muscular involvement. Definition of…
  • Abstract Number: 1269 • 2014 ACR/ARHP Annual Meeting

    Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique

    Christophe Deligny1, Maryvonne Dueymes2, Serge Arfi1, José Zécler3, Maia Forgues4, Véronique Dehlinger5, Michel DeBandt6, Lauren Brunier-Agot6, Remi Bellance7, Isabelle Lamaury8, Nadege Cordel8, Nicolas Baillet9, Gilbert. Cadelis10, Georges Jean Baptiste11 and Katlyne Polomat12, 1Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 2Immunology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, 3Respiratory, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, 4Internal medicine, Centre Hospitalier Andre Rosemon, Cayenne, French Guiana, 5Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort De France - Martinique, Martinique, 6Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, 7National center for rare neuromuscular disorders, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, 8Infectious diseases, dermatology and internal medicine, Centre Hospitalier universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, 9internal medicine, Centre Hospitalier de la Basse Terre, Basse Terre, Guadeloupe, 10Respiratory, Cnetre Hospitalier Universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, 11Rheumatology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Guadeloupe, 12Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique

    Background/Purpose : There is no population based epidemiologic studies of antisynthetase syndrome (ASS). We described characteristics and epidemiology of this disease in Martinique, populated by…
  • Abstract Number: 1936 • 2013 ACR/ARHP Annual Meeting

    Quality Of Care In Patients At Risk For Pulmonary Involvement:  Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic

    Michael G. Indelicato1, Janet E. Lewis2, Vincent J. Giuliano3 and Donald L. Kimpel4, 1Rheumatology, University of Virginia, Charlottesville, VA, 2Rheumatology, University of Virginia School of Medicine, Charlottesville, VA, 3University of Virginia, Charlottesville, VA, 4Rheumatology and Immunology, University of Virginia School of Medicine, Charlottesville, VA

    Background/Purpose: As a quality assessment tool to evaluate patient care in a general Rheumatology Clinic, we determined the frequency of screening for pulmonary hypertension and…
  • Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting

    Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis

    Christine McBurney1, Rohit Aggarwal2, Kevin Gibson3, Kathleen Lindell4, Carl Fuhrman5, Diane Koontz6, Frank Schneider7, Naftali Kaminski4 and Chester V. Oddis8, 1Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, 5Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, 6Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Anatomic Pathology Department, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…
  • Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting

    Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health

    Lisa G. Rider1, Adrienne L. Yip2, Iren Horkayne-Szakaly3, Rita Volochayev2, Joseph A. Shrader4, Maria L. Turner5, Heidi H. Kong5, Minal S. Jain4, Anna V. Jansen1, Chester V. Oddis6, Thomas A. Fleisher7 and Frederick W. Miller1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3Joint Pathology Center, Silver Spring, MD, 4Rehabilitation Medicine, Rehab Medicine, NIH Clinical Center, Bethesda, MD, 5Dermatology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, 6Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Laboratory Medicine, Laboratory Medicine, NIH Clinical Center, Bethesda, MD

    Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…
  • Abstract Number: 1952 • 2012 ACR/ARHP Annual Meeting

    The Effect of CXCL10 Blockade in C Protein-Induced Myositis

    Jinhyun Kim1, Jiyong Choi2, Sung Hae Chang3, Ki Chul Shin4, Sung-Hye Park5, Hye Won Kim6, Hye Jin Oh4, Myeong Jae Yoon7, Bong Seung Ku8, Eun Young Lee6, Eun Bong Lee3, Hiroshi Kawachi9, Hitoshi Kohsaka10 and Yeong Wook Song11, 1Department of Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 4Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, 5Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 7Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, 8Rheumatology, Department of Internal Medicine, School of Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, South Korea, 9Department of Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 10Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 11Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea

    Background/Purpose: CXCL10 (also called interferon-γ-inducible protein 10 [IP-10]) is a chemokine that plays a critical role in the infiltration of T cell in autoimmune disease…
  • Abstract Number: 1928 • 2012 ACR/ARHP Annual Meeting

    Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients

    Ragnar Gunnarsson1, Inge-Margrethe Gilboe1, Torhild Garen2 and Øyvind Molberg3, 1Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway

    Background/Purpose: Even though 40 years have passed since MCTD was defined as a distinct disorder, there is still no evidence based therapy available. The choice…
  • Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting

    Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease

    Kyle P. Chiang1, Varun Gauba1, Darin Lee1, Minh-Ha T. Do1, Jie J. Zhou2, Feng Wang2, Ying Buechler1, Leslie Nangle1, Zhiwen Xu2, John Mendlein1, Melissa Ashlock1 and Jeffrey M. Greve1, 1aTyr Pharma, San Diego, CA, 2Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong

    Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
  • Abstract Number: 754 • 2012 ACR/ARHP Annual Meeting

    The Functional Index-3 in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance

    Christopher Chong1, Orla Ni Mhuircheartaigh1, Helene Alexanderson2, Tanaz A. Kermani3, Cynthia S. Crowson4, Abigail B. Green4, Ann M. Reed5 and Floranne C. Ernste6, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Dept of Neuroscience, Care Science and Society, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology, University of California Los Angeles, Los Angeles, CA, 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 5Rheumatology, Mayo Clinic, Rochester, MN, 6Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: Although muscle fatigue is a major source of functional impairment in dermatomyositis (DM) and polymyositis (PM), few valid and reliable methods for efficient evaluation…
  • Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting

    Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group

    MIchelle Jung1, Murray Baron2, Marie Hudson3, Ashley Bonner4, Janet E. Pope5 and Canadian Scleroderma Research Group6, 1Western University, London, ON, Canada, 2Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Jewish General Hospital, McGill University, Montreal, QC, Canada, 4McMaster University, Hamilton, ON, Canada, 5Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 6Montreal, QC, Canada

    Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc).  The aim of this study was to determine such clinical information from the…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology